尿液生物标志物预测危重症急性肾损伤进展及不良结局
Dublin急性生物标志物组评估研究为前瞻性队列,纳入717例危重症患者,其中186例在入院7天内发生AKI。在早期1-2期AKI时检测14种尿液生物标志物,发现8种与进展独立相关,最佳预测因子为胱抑素C、IL-18、白蛋白和NGAL;这些标志物也与30天内RRT或死亡独立相关。
要点
- 早期1-2期AKI时尿液胱抑素C、IL-18、白蛋白和NGAL独立预测AKI进展。
- IL-18、NGAL、白蛋白和MCP-1独立预测30天内RRT或死亡。
- 上述标志物经进一步验证后可能辅助危重症AKI的诊断与预后评估。
核心结论
- 在14种新型尿液生物标志物中,胱抑素C、IL-18、白蛋白和NGAL是早期1-2期AKI进展的最佳预测因子。
- 这些标志物经进一步验证后可能有助于危重症患者AKI的诊断与预后评估及管理。
研究设计与样本
- Dublin急性生物标志物组评估研究为前瞻性队列研究,纳入717例危重症患者。
- 主要(诊断)分析评估早期1期或2期AKI时生物标志物水平预测7天内进展至更高AKI分期、肾脏替代治疗(RRT)或死亡的能力。
- 次要(预后)分析探究生物标志物水平与30天内RRT或死亡的关联。
主要发现
- 7天内共有186例患者发生AKI。
- 主要分析中,14种生物标志物中有8种与AKI进展独立相关。
- 最佳预测因子为胱抑素C(aOR 5.2;95%CI 1.3-23.6)、IL-18(aOR 5.1;95%CI 1.8-15.7)、白蛋白(aOR 4.9;95%CI 1.5-18.3)和NGAL(aOR 4.6;95%CI 1.4-17.9)。
- ROC和净重分类指数分析同样显示这些生物标志物改善预测。
- 在1-3期AKI的次要分析中,IL-18、NGAL、白蛋白和单核细胞趋化蛋白-1也与30天内RRT或死亡独立相关。
临床怎么用
- 对危重症早期1-2期AKI患者,检测尿液胱抑素C、IL-18、白蛋白和NGAL可能帮助识别进展高风险者。
- 这些标志物经进一步验证后,或可辅助AKI诊断与预后评估并指导管理。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Acute kidney injury (AKI) is common in hospitalized patients and is associated with high morbidity and mortality. The Dublin Acute Biomarker Group Evaluation study is a prospective cohort study of critically ill patients (n = 717). We hypothesized that novel urinary biomarkers would predict progression of AKI and associated outcomes. METHODS: The primary (diagnostic) analysis assessed the ability of biomarkers levels at the time of early Stage 1 or 2 AKI to predict progression to higher AKI stage, renal replacement therapy (RRT) or death within 7 days of intensive care unit admission. In the secondary (prognostic) analysis, we investigated the association between biomarker levels and RRT or death within 30 days. RESULTS: In total, 186 patients had an AKI within 7 days of admission. In the primary (diagnostic) analysis, 8 of the 14 biomarkers were independently associated with progression. The best predictors were cystatin C [adjusted odds ratio (aOR) 5.2; 95% confidence interval (CI) 1.3-23.6], interleukin-18 (IL-18; aOR 5.1; 95% CI 1.8-15.7), albumin (aOR 4.9; 95% CI 1.5-18.3) and neutrophil gelatinase-associated lipocalin (NGAL; aOR 4.6; 95% CI 1.4-17.9). Receiver-operating characteristics and net reclassification index analyses similarly demonstrated improved prediction by these biomarkers. In the secondary (prognostic) analysis of Stages 1-3 AKI cases, IL-18, NGAL, albumin and monocyte chemotactic protein-1 were also independently associated with RRT or death within 30 days. CONCLUSIONS: Among 14 novel urinary biomarkers assessed, cystatin C, IL-18, albumin and NGAL were the best predictors of Stages 1-2 AKI progression. These biomarkers, after further validation, may have utility to inform diagnostic and prognostic assessment and guide management of AKI in critically ill patients.
引用
- Duff S, Irwin R, Cote JM, et al. Urinary biomarkers predict progression and adverse outcomes of acute kidney injury in critical illness. Nephrol Dial Transplant. 2022. PMID: 34491355. doi:10.1093/ndt/gfab263
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。